Amphastar Pharmaceuticals Inc. logo

Amphastar Pharmaceuticals Inc. (29A)

Market Closed
1 Jun, 20:00
XDUS XDUS
15. 86
-0.18
-1.12%
- Market Cap
- P/E Ratio
- Div Yield
0 Volume
- Eps
16.04
Previous Close
Add Transaction
Day Range
15.77 15.97
Year Range
14.21 26.5
Want to track 29A and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

29A closed Monday lower at €15.86, a decrease of -1.12% from Friday's close, completing a monthly decrease of -0.72% or -€0.12. Over the past 12 months, 29A stock lost -29.47%.
29A is not paying dividends to its shareholders.
The last earnings report, released on May 05, 2026, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.32%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 5 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).

29A Chart

Amphastar Pharmaceuticals Tackles BAQSIMI Discount Pressure, Keeps Sales Outlook

Amphastar Pharmaceuticals Tackles BAQSIMI Discount Pressure, Keeps Sales Outlook

Amphastar Pharmaceuticals NASDAQ: AMPH executives said the company is taking steps to address rebate and discounting pressure on BAQSIMI while maintaining its full-year revenue outlook, according to remarks at the BofA Annual Healthcare Conference.

Marketbeat | 2 weeks ago
Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seekingalpha | 2 weeks ago
Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2026 Earnings Call Transcript

Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2026 Earnings Call Transcript

Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2026 Earnings Call Transcript

Seekingalpha | 3 weeks ago

Amphastar Pharmaceuticals Inc. (29A) FAQ

What is the stock price today?

The current price is €15.86.

On which exchange is it traded?

Amphastar Pharmaceuticals Inc. is listed on XDUS.

What is its stock symbol?

The ticker symbol is 29A.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Amphastar Pharmaceuticals Inc. ever had a stock split?

No, there has never been a stock split.

Amphastar Pharmaceuticals Inc. Profile

Specialty Retail Industry
Consumer Discretionary Sector
Yongfeng Zhang CEO
XDUS Exchange
US03209R1032 ISIN
US Country
2,028 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Amphastar Pharmaceuticals, Inc. is a bio-pharmaceutical company that focuses on the development, manufacturing, marketing, and sale of both generic and proprietary injectable, inhalation, and intranasal products. The company has a global footprint with operations in the United States, China, and France. Established in 1996 and based in Rancho Cucamonga, California, Amphastar Pharmaceuticals caters to a diverse range of medical needs, emphasizing solutions for severe hypoglycemia, opioid overdose, adrenocortical insufficiency, intermittent asthma, and deep vein thrombosis among others. Additionally, the company engages in the distribution of insulin APIs and is involved in the development of generic, biosimilar, and innovative analytical technologies.

Products and Services

  • BAQSIMI - A nasal spray designed for severe hypoglycemia treatment.
  • Primatene Mist - An over-the-counter epinephrine inhalation product for mild asthma symptoms.
  • Enoxaparin - Used to prevent and treat deep vein thrombosis.
  • REXTOVY and Naloxone - Intended for the reversal of opioid overdose.
  • Glucagon Emergency Kit - A kit for injection in emergency situations to treat hypoglycemia.
  • Cortrosyn - A diagnostic agent used in screening for adrenocortical insufficiency.
  • Amphadase - An injection that aids the absorption and dispersion of other injected drugs.
  • Epinephrine Injection - For the management of allergic reactions.
  • Lidocaine Jelly and Topical Solution - Anesthetics for urological and various other procedures.
  • Phytonadione Injection - A vitamin K1 injection for newborns.
  • Emergency Syringe Products - Various products designed for emergency medical use.
  • Morphine Injection - For use with patient-controlled analgesia pumps.
  • Lorazepam Injection - Used for anxiety relief during surgery and medical procedures.
  • Neostigmine Methylsulfate Injection - Treats myasthenia gravis and reverses the effects of muscle relaxants.
  • Isoproterenol Hydrochloride Injection - Manages mild or transient episodes of heart block.
  • Ganirelix Acetate Injection - Used for the inhibition of premature luteinizing hormone surges.
  • Vasopressin - Administered to increase blood pressure in vasodilatory shock.
  • Regadenoson - A stress agent used in radionuclide myocardial perfusion imaging.
  • Insulin API Distribution - Distributes recombinant human and porcine insulin APIs.
  • Generic Product Candidates - Focuses on developing injectable, inhalation, and analytical technologies.
  • Biosimilar Product Candidates - Develops alternatives to existing biologic medicines.
  • Intranasal Epinephrine - Under development for treating allergic reactions.

Contact Information

Address: 11570 6th Street
Phone: 909 980 9484